Press release
Illumina partners with centers across France to advance a precision medicine approach for patients with late-stage cancer
Joint study will assess clinical value of comprehensive genomic profiling (CGP) on cancer therapy options in patients with advanced disease SAN DIEGO, Feb. 3,
About this update from Illumina, Inc.
[{"type":"text","content":"Joint study will assess clinical value of comprehensive genomic profiling (CGP) on cancer therapy options in patients with advanced disease\n\n\nSAN DIEGO, Feb. 3, 2022 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN), today announced an agreement with the Jean Perrin Center at the Clermont-Ferrand University Hospital in France to assess the clinical value of comprehensive genomic profiling (CGP) in cancer therapy options in patients with late-stage disease compared to use of current standard of care, including small panel tests. Evidence from the CELIA (comprehensive genomic profiling impact) research study will be used to support a precision medicine approach for patients with late-stage cancer within the French healthcare system.\n\n \n \n \n \n \n \n\n \nThe Jean Perrin Center, with participation from the Toulouse Oncopole and the Bordeaux University Hospital Center, will analyze biopsy samples from patients with advanced colorectal, breast, melanoma or lung cancer using CGP enabled by Illumina's TruSight™ Oncology 500 assay.\n\"We are pleased to be working with the Jean Perrin Center which is leading this important study that will contribute to the growing international evidence base that puts CGP at the forefront of precision oncology medicine,\" said Phil Febbo, MD, Chief Medical Officer at Illumina. \"By assessing many mutations and biomarkers simultaneously to reveal the unique molecular profile of a tumor, CGP is helping to rapidly deliver actionable insights to patients and physicians, and improve outcomes.\" \nTruSight™ Oncology 500 assay can look for the presence of mutations and biomarkers from over 500 genes simultaneously to reveal the specific molecular profile of a cancer sample. This profile can then be matched against precision medicine treatments known to act on specific gene alterations or biomarkers. This approach will be compared by researchers with standard of care testing, including small panel tests that cover a limited range of biomarkers of interest for each cancer type.\n\"CGP is being increasingly used in cancer centers throughout Europe, including France. Our goal is to confirm the clear clinical utility in order to make next-generation sequencing for metastatic cancer more broadly included in European and national clinical guidelines,\" said Professor Frédérique Penault-Llorca, General Director of th...